PetMed Express Appoints Tamar Elkeles to Board as Independent Director

What Happened
PetMed Express, Inc. (PETS) announced that its board appointed Tamar Elkeles, Ph.D., as a director effective September 17, 2026, increasing the board to five members. The board determined Dr. Elkeles is independent under Nasdaq rules and immediately assigned her to the Compensation & Human Capital Committee and the Corporate Governance & Nominating Committee. She will serve until the 2027 annual meeting or until her successor is qualified.

Key Details

• Appointment effective: September 17, 2026; board size increased to 5 directors.
• Committee assignments: Compensation & Human Capital Committee; Corporate Governance & Nominating Committee.
• Background: Dr. Elkeles, age 57, has 30+ years in human capital, enterprise software and tech; recent roles include CHRO of XCOM Labs and Senior Advisor at East Wind Advisors; serves on several public and private company boards.
• Governance/compensation: Board will compensate her under the company’s Non‑Employee Director Compensation Program (see 2026 Form 10‑K) and intends to enter into the company’s standard director indemnification agreement.
• Independence & disclosures: Board found her independent; no family relationships or related‑party transactions requiring disclosure under Item 404(a) of Regulation S‑K.
• PR filed: Company issued a press release on September 21, 2026 (furnished as Exhibit 99.1).

Why It Matters
This is a governance update: PetMed Express added an experienced human capital and governance professional to strengthen oversight of compensation, board governance and talent strategy. For investors, the change signals the board’s focus on human capital and corporate governance as the company pursues its strategic priorities. Compensation and indemnification terms follow the company’s standard non‑employee director practices, and no related‑party issues were disclosed.